Navigation Links
Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains

May 31, 2012 (Bronx, NY) The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.

In a study published last September in Nature Medicine, Einstein researchers demonstrated that some animals inoculated with the altered M. smegmatis are able to generate a robust immune response when challenged with M. tuberculosis.

Despite widespread use of the 90-year-old Bacille Calmette-Gurin (BCG) vaccine and the availability of several anti-TB drugs, TB remains a major global health problem. In 2010, 8.8 million people fell ill with TB and 1.4 million died of the disease, according to the World Health Organization. The situation has worsened in recent years with the rise of multi drug-resistant TB (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), which are especially common in Africa and Asia.

"Novel therapies for TB are urgently needed, particularly a new and effective vaccine," said William Jacobs, Jr., Ph.D., professor of microbiology & immunology and of genetics at Einstein and a Howard Hughes Medical Institute investigator, who led the development of the new vaccine approach and is principal investigator of the NIH grant.

Einstein's vaccine approach emerged from basic studies of how TB bacteria outwit the immune system. Dr. Jacobs and his colleagues worked with M. smegmatis, which in high doses is lethal in mice but does not harm humans. The researchers created a version of M. smegmatis lacking a set of genes, known as ESX-3, considered crucial for evading host immunity. When high doses of the altered bacteria were infused into mice, it became clear that bacteria lacking the ESX-3 genes could no longer evade their hosts' immune system: the mice controlled and cleared the infection through a robust T-cell response the same response a successful TB vaccine would elicit.

Unfortunately, Dr. Jacobs found that removing the same set of genes from M. tuberculosis killed the bacterium which meant M. tuberculosis could not be manipulated in this way to make a vaccine. But Dr. Jacobs and his colleagues found a way around this stumbling block. They took the M. smegmatis bacteria lacking ESX-3 and inserted the analogous set of M. tuberculosis ESX-3 genes. These M. smegmatis bacteria were then infused into mice, which once again fought off the infection. And eight weeks later, when the mice were challenged with high doses of M. tuberculosis which kills mice as well as people these "vaccinated" mice lived much longer than control mice: an average survival time of 135 days vs. 54 days.

Of particular note was the markedly reduced level of TB bacteria found in the animals' tissues. "Most notably," said Dr. Jacobs, "those vaccinated animals that survived for more than 200 days had livers that were completely clear of TB bacteria, and nobody has ever seen that before." Only about one in five mice showed this robust response indicating that the vaccine must be improved before it can be considered sufficiently effective.

With funds from the NIH grant, the researchers will try to make the vaccine more effective by further genetically modifying the bacteria that it uses. They will also develop a manufacturing process for making batches of the vaccine for human use and develop assays for identifying the most potent batches.

The grant "Vaccines for Extensively Drug Resistant Tuberculosis" (1R01AI098925-01) was awarded by National Institute of Allergy And Infectious Diseases, a division of the NIH.


Contact: Kim Newman
Albert Einstein College of Medicine

Related medicine news :

1. State Sen. Jeff Klein launches Einsteins new lab
2. Einstein researcher helps lead consortium for $10 million X Prize to sequence genomes of 100 centenarians
3. Einstein College of Medicine receives $5.7 million for developmental disabilities research
4. Einstein to utilize electronic medical records system to analyze HIV/AIDS in central Africa
5. Einstein scientists find crucial molecule involved in spread of breast cancer
6. Einstein secures $11 million to continue research on brain aging and Alzheimers disease
7. Einstein Montefiore lung specialist to receive award for work with 9/11 rescue workers
8. Feinstein scientists identify abnormal disease pathway in dystonia
9. Susan Band Horwitz, Ph.D., of Einstein, receives lifetime achievement award in cancer research
10. Einstein-Montefiore researcher will test nanoparticles against pancreatic cancer
Post Your Comments:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and ... their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took ... the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
Breaking Medicine Technology: